Figure 6D illustrates the data involving CRS and TrkB-shRNA. The usage of TrkB-shRNA evidently prevented the decreasing effects of oroxylin A on the FST immobility [ANOVA: F (6, 77) = 34.226, p < 0.01] and TST immobility [ANOVA: F (6, 77) = 27.338, p < 0.01] of mice subjected to CRS (n = 12, p < 0.01). Moreover, the usage of TrkB-shRNA evidently prevented the enhancing effects of oroxylin A on the sucrose preference of mice subjected to CRS [ANOVA: F (6, 77) = 15.432, p < 0.01] (n = 12, p < 0.01). This evidence concerns the gene NTRK2 and congenital rubella syndrome.